Treatment of glioblastoma with poly(isohexyl cyanoacrylate) nanoparticles.
Standard
Treatment of glioblastoma with poly(isohexyl cyanoacrylate) nanoparticles. / Wohlfart, Stefanie; Khalansky, Alexander S; Bernreuther, Christian; Michaelis, Martin; Cinatl, Jindrich; Glatzel, Markus; Kreuter, Jörg.
in: INT J PHARMACEUT, Jahrgang 415, Nr. 1-2, 1-2, 2011, S. 244-251.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Treatment of glioblastoma with poly(isohexyl cyanoacrylate) nanoparticles.
AU - Wohlfart, Stefanie
AU - Khalansky, Alexander S
AU - Bernreuther, Christian
AU - Michaelis, Martin
AU - Cinatl, Jindrich
AU - Glatzel, Markus
AU - Kreuter, Jörg
PY - 2011
Y1 - 2011
N2 - Glioblastomas belong to the most devastating cancer diseases. For this reason, polysorbate 80 (Tween 80)-coated poly(isohexyl cyanoacrylate) (PIHCA) (Monorex) nanoparticles loaded with doxorubicin were developed and tested for their use for the treatment of glioblastomas. The preparation of the nanoparticles resulted in spherical particles with high doxorubicin loading. The physico-chemical properties and the release of doxorubicin from the PIHCA-nanoparticles were analysed, and the influence on cell viability of the rat glioblastoma 101/8-cell line was investigated. In vitro, the empty nanoparticles did not show any toxicity, and the anti-cancer effects of the drug-loaded nanoparticles were increased in comparison to doxorubicin solution, represented by IC(50) values. The in vivo efficacy was then tested in intracranially glioblastoma 101/8-bearing rats. Rats were treated with 3 × 1.5mg/kg doxorubicin and were sacrificed 18 days after tumour transplantation. Histological and immunohistochemical analyses were carried out to assess the efficacy of the nanoparticles. Tumour size, proliferation activity, vessel density, necrotic areas, and expression of glial fibrillary acidic protein demonstrated that doxorubicin-loaded PIHCA-nanoparticles were much more efficient than the free drug. The results suggest that poly(isohexyl cyanoacrylate) nanoparticles hold great promise for the non-invasive therapy of human glioblastomas.
AB - Glioblastomas belong to the most devastating cancer diseases. For this reason, polysorbate 80 (Tween 80)-coated poly(isohexyl cyanoacrylate) (PIHCA) (Monorex) nanoparticles loaded with doxorubicin were developed and tested for their use for the treatment of glioblastomas. The preparation of the nanoparticles resulted in spherical particles with high doxorubicin loading. The physico-chemical properties and the release of doxorubicin from the PIHCA-nanoparticles were analysed, and the influence on cell viability of the rat glioblastoma 101/8-cell line was investigated. In vitro, the empty nanoparticles did not show any toxicity, and the anti-cancer effects of the drug-loaded nanoparticles were increased in comparison to doxorubicin solution, represented by IC(50) values. The in vivo efficacy was then tested in intracranially glioblastoma 101/8-bearing rats. Rats were treated with 3 × 1.5mg/kg doxorubicin and were sacrificed 18 days after tumour transplantation. Histological and immunohistochemical analyses were carried out to assess the efficacy of the nanoparticles. Tumour size, proliferation activity, vessel density, necrotic areas, and expression of glial fibrillary acidic protein demonstrated that doxorubicin-loaded PIHCA-nanoparticles were much more efficient than the free drug. The results suggest that poly(isohexyl cyanoacrylate) nanoparticles hold great promise for the non-invasive therapy of human glioblastomas.
KW - Animals
KW - Male
KW - Immunohistochemistry
KW - Surface Properties
KW - Solubility
KW - Rats
KW - Cell Line, Tumor
KW - Rats, Wistar
KW - Cell Proliferation/drug effects
KW - Microscopy, Electron, Scanning
KW - Particle Size
KW - Xenograft Model Antitumor Assays
KW - Brain Neoplasms/drug therapy/pathology
KW - Cell Survival/drug effects
KW - Cyanoacrylates/chemistry
KW - Doxorubicin/administration & dosage/therapeutic use
KW - Drug Carriers/chemistry
KW - Drug Compounding
KW - Glioblastoma/drug therapy/pathology
KW - Nanoparticles/chemistry
KW - Animals
KW - Male
KW - Immunohistochemistry
KW - Surface Properties
KW - Solubility
KW - Rats
KW - Cell Line, Tumor
KW - Rats, Wistar
KW - Cell Proliferation/drug effects
KW - Microscopy, Electron, Scanning
KW - Particle Size
KW - Xenograft Model Antitumor Assays
KW - Brain Neoplasms/drug therapy/pathology
KW - Cell Survival/drug effects
KW - Cyanoacrylates/chemistry
KW - Doxorubicin/administration & dosage/therapeutic use
KW - Drug Carriers/chemistry
KW - Drug Compounding
KW - Glioblastoma/drug therapy/pathology
KW - Nanoparticles/chemistry
M3 - SCORING: Journal article
VL - 415
SP - 244
EP - 251
JO - INT J PHARMACEUT
JF - INT J PHARMACEUT
SN - 0378-5173
IS - 1-2
M1 - 1-2
ER -
